XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2

Accrued Liabilities

9 Months Ended

Sep. 30, 2021

Payables and Accruals [Abstract]

Accrued Liabilities

ACCRUED LIABILITIES

(in millions)			September 30, 2021									December 31, 2020
Employee compensation and benefits			$	54.0								$	48.9
Legal accrual			48.0									—
Accrued taxes payable			17.3									4.3
Refunds payable and reserves			8.9									9.3
Short-term contingent consideration			3.3									3.4
Accrued royalties			5.0									3.8
Purchase commitment			5.2									—
Other accrued liabilities			21.5									9.4
Total accrued liabilities			$	163.2								$	79.1

During the quarter ended September 30, 2021, the Company accrued $48.0 million for a potential settlement of the qui tam lawsuit against Crescendo Bioscience, Inc. and the Company. Refer to Note 13 for additional information.

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration